Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. uri icon

authors

  • Bateman, Randall J
  • Supnet, Charlene
  • Benzinger, Tammie L S
  • Gordon, Brian A
  • Ibanez, Laura
  • Klein, Gregory
  • Baudler, Monika
  • Doody, Rachelle S
  • Delmar, Paul
  • Kerchner, Geoffrey A
  • Bittner, Tobias
  • Li, Yan
  • Wojtowicz, Jakub
  • Bonni, Azad
  • Fontoura, Paulo
  • Hofmann, Carsten
  • Kulic, Luka
  • Hassenstab, Jason
  • Andrew Aschenbrenner, PhD
  • Perrin, Richard J
  • Cruchaga, Carlos
  • Renton, Alan E
  • McDade, Eric M
  • Xiong, Chengjie
  • Goate, Alison A
  • Morris, John C
  • Holtzman, David M
  • Snider, B Joy
  • Mummery, Catherine
  • Brooks, William S
  • Wallon, David
  • Berman, Sarah B
  • Roberson, Erik
  • Llibre-Guerra, Jorge J
  • Masters, Colin L
  • Galasko, Douglas R
  • Jayadev, Suman
  • Sanchez-Valle, Rachel
  • Pariente, Jeremie
  • Kinsella, Justin
  • van Dyck, Christopher H
  • Gauthier, Serge
  • Hsiung, Ging-Yuek Robin
  • Masellis, Mario
  • Clifford, David B
  • Dubois, Bruno
  • Honig, Lawrence S
  • Jack, Clifford R
  • Daniels, Alisha
  • Aguillón, David
  • Allegri, Ricardo
  • Chhatwal, Jasmeer
  • Day, Gregory
  • Fox, Nick C
  • Huey, Edward
  • Atri, Alireza
  • Ikeuchi, Takeshi
  • Jucker, Mathias
  • Lee, Jae-Hong
  • Levey, Allan I
  • Levin, Johannes
  • Lopera, Francisco
  • Roh, JeeHoon
  • Rosa-Neto, Pedro
  • Schofield, Peter R
  • Mills, Susan L
  • Santacruz, Anna M
  • Wang, Guoqiao

publication date

  • April 2025